Hiroyuki Yasojima

3PUBLICATIONS

26CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Apr 16, 2026

Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.

|Mar 19, 2026

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando

|Nov 04, 2025

Genomically determined subtypes and clinicopathological features as predictors of the efficacy of preoperative chemotherapy combined with HER2-targeted therapy for early-stage HER2-positive breast cancer.

Sayumi Imamura, Kiyoshi Mori, Hiroyuki Yasojima

Pageof 1

Frequent Collaborators

3 joint publications

Norikazu Masuda

2 joint publications

Hiroko Bando

2 joint publications

Shigenori E Nagai

2 joint publications

Masakazu Toi

2 joint publications

Rikiya Nakamura

1 joint publications

Tetsuro Sasada

1 joint publications

Kiyoshi Mori

1 joint publications

Chie Hayashi

1 joint publications

Takashi Yamanaka

1 joint publications

Hideo Shigematsu

Frequent Collaborators

3 joint publications

Norikazu Masuda

2 joint publications

Hiroko Bando

2 joint publications

Shigenori E Nagai

2 joint publications

Masakazu Toi